EUCTR2008-001211-37-IT进行中（未招募）不适用
STUDIO MULTICENTRICO, RANDOMIZZATO, IN DOPPIO CIECO, A GRUPPI PARALLELI, CONTROLLATO VERSO PLACEBO PER VALUTARE LE COMBINAZIONI A DOSE FISSA DI SOLIFENACINA SUCCINATO (6 MG E 9 MG) IN ASSOCIAZIONE A TAMSULOSINA CLORIDRATO OCAS 0.4 MG E TAMSULOSINA CLORIDRATO OCAS 0.4 MG IN MONOTERAPIA, IN SOGGETTI DI SESSO MASCHILE AFFETTI DA SINTOMATOLOGIA DELLE BASSE VIE URINARIE (LUTS) ASSOCIATA AD IPERPLASIA PROSTATICA BENIGNA (BPH) CON PREVALENTE SINTOMATOLOGIA DA ACCUMULO - Neptune
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,452
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •At study entry (Visit 1): 1. Male subjects aged ≥45 years. 2. Written informed consent has been obtained. 3.Subject is willing and able to complete the micturition diary and questionnaires correctly. 4. Voiding symptoms (including incomplete emptying of the bladder, intermittency, weak stream or hesitancy) and storage symptoms (including frequency and urgency), diagnosed as LUTS associated with BPH for ≥3 months. 5. Total I-PSS of ≥13. 6. Substantial amount of storage symptoms for ≥3 months (at the discretion of the investigator, expected to have a micturition frequency of ≥8 and at least 2 episodes of urgency with PPIUS grade 3 or 4 per day). 7. A maximum urinary flow rate of ≥4.0 mL/s and ≤12.0 mL/s, with a voided volume of ≥120 mL during free flow. At randomization (Visit 2): 8. Total I-PSS of ≥13. 9. Maximum urinary flow rate of ≥4.0 mL/s and ≤12.0 mL/s, with a voided volume of ≥120 mL during free flow. 10. A micturition frequency of ≥8 and at least 2 episodes of urgency (PPIUS grade 3 or 4) per day on average during the 3 day micturition diary. 11. Subject continues to meet all inclusion criteria of Visit 1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •At study entry(V1):1.Any significant PVR >150mL 2.Prostate with estimated weight ≥75g as assessed by transvesical or transrectal ultrasound.3.Evidence of symptomatic urinary tract infection or known history or diagnosis of any of the following urinary conditions:- Recurrent symptomatic urinary tract infection -Urological Pain Syndromes as classified by the EAU Guideline on Chronic Pelvic Pain,update 2008 -Chronic prostatitis comprising type A (inflammatory) and type B (noninflammatory) -Evidence of current symptomatic or asymptomatic urolithiasis -Previous or current malignant disease of pelvic and urogenital organs with exception of carcinoma of bladder if longer than 5 years recurrence-free -Previous pelvic radiation therapy -Previous surgery to bladder neck or prostate -Bladder neck stenosis -Urethral stricture.4.Narrow angle glaucoma, myasthenia gravis, severe gastrointestinal condition (incl.toxic megacolon),hiatal hernia,gastroesophageal reflux or subject is at risk for these conditions;urinary or gastric retention or any other medical condition,which in the opinion of the investigator presents a contraindication for the use of anticholinergics.5.Clinically significant significant cardiovascular or cerebrovascular diseases within 6 months prior to V1.6.Any other cardiovascular or cerebrovascular disease which in the opinion of the investigator makes the subject unsuitable for participation in study.7.Non-drug treatment for LUTS associated with BPH or OAB,including electrostimulation therapy at start of the study or start of a bladder training program during the 2weeks prior to or during the study.8.Use of prohibited concomitant medication -Other pharmacological treatment used for LUTS/BPH, such as alpha-adrenoceptor (α-AR)-antagonists and plant extracts.-5α-reductase inhibitors (within 3 months prior to V1) -Other drugs which may influence the pharmacodynamic effects of solifenacin or tamsulosin,phosphodiesterase type 5 (PDE5) inhibitors,anticholinergics,or CYP 3A4 inhibitors or inducers that may influence the PK of solifenacin or tamsulosin.9.Use of combined α/ß-AR-antagonists,α2-agonists,oral and systemic β-agonists,cholinergics and any drugs with cholinergic or anticholinergic side effects,or diuretics However,long term dosage stable therapy (>1month prior to randomization) is permitted.10.Diabetic neuropathy.11.Planned cataract surgery during Study 905-CL-055 or Study 905-CL-057 or within 30 days after completion of any of the studies.12.Severe renal impairment (including hemodialysis) or moderate or severe hepatic impairment.13.Known polyuria.14.Known or suspected hypersensitivity to solifenacin,other anticholinergics,tamsulosina,other α-AR-antagonists,lactose or any of the other excipients of study medication.15.Any clinically significant condition,which in the opinion of the investigator makes the subject unsuitable for the trial.16.Participation in any clinical trial within 30 days (or limit set by national law,whichever is longer) prior to randomization.17.Employee of Astellas, of CROs involved or of investigator site executing study.At randomization (V2):18.Subject did not complete micturition diary or I-PSS questionnaire according to instructions.19.Significant PVR>150 mL.20.Total daily urine volume >3L/day on any day during the 3days of micturition diary.21.Any clinically significant abnormal ECG,which in the opinion of the investigator makes the subject unsuitable for the trial.22.
研究者
相似试验
进行中（未招募）
1 期
Estudio multicéntrico de 2 partes para evaluar la farmacocinética, la seguridad y la tolerabilidad del aprepitant en pacientes pediátricos sometidos a una intervención quirúrgica.A Multicenter, 2-Part Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aprepitant in Pediatric Patients Undergoing Surgery.Prevención de nauseas y vómitos postoperatorios en pacientes pediátricos.Prevention of Postoperative nausea and vomiting in pediatric patients.MedDRA version: 9.1Level: LLTClassification code 10036901Term: Prophylaxis against postoperative nausea and vomitingEUCTR2008-003178-17-ESMerck & Co., Inc.98
进行中（未招募）
不适用
Ensayo Clínico multicéntrico, doble ciego, para la comparación in vivo del tamaño de las pápulas cutáneas producidas por los extractos alergénicos nativo, despigmentado y despigmentado polimerizado de Arachis hypogaea.A multicenter study, double-blind, in vivo comparison of the skin wheal size induced by the native, depigmented and depigmented-polymerized allergenic extracts of Arachis hypogaea.EUCTR2010-019355-22-ESaboratorios LETI, S.L. Unipersonal30
进行中（未招募）
不适用
Estudio multicéntrico, doble ciego, con doble simulación y cruzado con dos fases, de Nasalfent (citrato de fentanilo, aerosol nasal) comparado con comprimidos de sulfato de morfina de liberación inmediata, en el tratamiento del dolor oncológico irruptivo (DOI) en sujetos que reciben terapia opioide de baseEUCTR2006-003493-97-ESArchimedes Development Ltd.200
进行中（未招募）
1 期
ESTUDIO DE SEGUIMIENTO, MULTICÉNTRICO, DOBLECIEGO Y DOBLE SIMULACIÓN, PARA EVALUAR LASEGURIDAD A LARGO PLAZO DE LACOSAMIDA (200 A600 MG/DÍA) FRENTE A CARBAMAZEPINA (400 A 1.200MG/DÍA), ADMINISTRADAS EN MONOTERAPIA, ENSUJETOS (IGUAL O MAYOR DE 16 AÑOS) AFECTOS DE CRISIS DE COMIENZO PARCIAL O TÓNICO-CLÓNICASGENERALIZADAS PROCEDENTES DEL ESTUDIO SP0993 //A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, FOLLOW UP STUDY EVALUATING THE LONG TERM SAFETY OF LACOSAMIDE (200 TO 600MG/DAY) IN COMPARISON WITH CARBAMAZEPINE (400 TO 1200MG/DAY), USED AS MONOTHERAPY IN SUBJECTS WITH PARTIAL ONSET OR GENERALIZED TONIC CLONIC SEIZURES 16 YEARS OF AGE OR OLDER COMING FROM THE SP0993 STUDYEUCTR2010-021238-74-ESSCHWARZ BIOSCIENCES GmbH600
进行中（未招募）
1 期
Estudio multicéntrico y doble ciego de la seguridad, la tolerabilidad y la inmunogenicidad de una vacuna antineumocócica conjugada (V114) en comparación con Prevenar 13? en lactantes sanos;A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13? in Healthy InfantsEUCTR2010-019775-29-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,110